# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2012 Earnings Results

**Report date:** 2012-07-25 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2012

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 6.09%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.90 | N/A | +234.57% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the earnings results, highlighting their commitment to pipeline development. They remain focused on growth opportunities.

**Key quotes:**

> We are pleased with our earnings performance this quarter.

> Our focus remains on advancing our pipeline and delivering value.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong earnings per share of $0.90 significantly exceeded expectations, contributing to a 6.09% increase in stock price. The company did not provide revenue figures or future guidance, but management's positive tone suggests confidence in ongoing projects. Investors may view this earnings surprise as a sign of the company's strong performance in a competitive market.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2012_